Ophthopedia

Ophthopedia Update:Platelet Factor 4 Attenuates inflammation of microglia and Protects Retinal Ganglion Cells in Retinal Excitotoxicity: Publication date: Available online 20 March 2025 Source: Experimental Eye Research Author(s): Daowei Zhang, Fangyuan Hu, Ting Li, Hongli Liu, Qian Li, Yun Cheng, Xuejin zhang, Ping Xu, Shenghai Zhang, Jihong Wu

Ophthopedia Update:Genome-wide methylation analysis unveils genes and pathways with altered methylation profiles in pterygium.: Publication date: Available online 20 March 2025 Source: Experimental Eye Research Author(s): Mathan L, Tejaswi Prasad, Mohammed Hameed Aslam, Aadhithiya T. Gr, Bharanidharan Devarajan, N. Venkatesh Prajna, K. Dharmalingam, Daipayan Banerjee

Ophthopedia Update:Ripasudil does not induce phospholipid accumulation in human corneal epithelial cells: Publication date: Available online 20 March 2025 Source: Experimental Eye Research Author(s): Fumiko Tazoe, Yuichiro Watanabe, Noriyuki Inoue, Mizuho Kanazawa, Atsushi Kasano, Toshihiro Inoue

Ophthopedia Update:Targeting BMP4 as a Therapeutic Strategy for Neovascularization and Fibrosis in Age-Related Macular Degeneration: Publication date: Available online 19 March 2025 Source: Experimental Eye Research Author(s): Rong Luan, Shuzhan Xu, Manhong Xu, Manqiao Wang, Xinyuan Huang, Jie Wang, Qingbo Li, Yi Gong, Juping Liu, Yan Shao, Xiaorong Li

Ophthopedia Update:期刊一览: Chou (p. 381) 等利用来自去标识化的全球电子病历数据库的数据,回顾性研究了司美格鲁肽是否会增加普通人群患非动脉炎性前部缺血性视神经病变(NAION)的风险。他们分析了 37 314 名仅患有2型糖尿病(T2DM)的参与者、129 690 名仅患有肥胖症的参与者,以及 130 216 名同时患有 T2DM 和肥胖症的参与者的数据。研究结果显示,在仅患有 T2DM、仅患有肥胖症,以及同时患有 T2DM 和肥胖症的个体中,使用司美格鲁肽并未与 NAION 风险增加相关。此外,在 1 年、2 年或 3 年的随访期内,该结果保持一致。研究人员总结,司美格鲁肽可能不会增加普通人群患 NAION 的风险,并指出,司美格鲁肽在改善血糖控制和心血管健康方面的潜在益处可能超过其与 NAION 相关的潜在风险。 #Ophthalmology #ophthotwitter #eyecare

Ophthopedia Update:This Issue at a Glance: Using data from a deidenti?ed global electronic medical records database, Chou et?al (p. 381) retrospectively investigated whether semaglutide increases the risk of nonarteritic anterior ischemic optic neuropathy (NAION) in the general population. They analyzed data from 37 314 participants with type 2 diabetes mellitus (T2DM) only, 129 690 participants with obesity only, and 130?216 participants with both T2DM and obesity. Semaglutide was not associated with an increased risk of NAION among individuals with T2DM only, obesity only, and both T2DM and obesity and the results were consistent across follow-up periods of 1, 2, or 3 years. #Ophthalmology #ophthotwitter #eyecare

Ophthopedia Update:En Breve: Utilizando datos de una base de datos de registros médicos electrónicos globales no identificados, Chou y otros (p. 381) realizaron una investigación retrospectiva sobre si la semaglutida aumenta el riesgo de neuropatía óptica isquémica anterior no arterítica (NAION) en la población general. Analizaron datos de 37.314 participantes con diabetes mellitus tipo 2 (T2DM) únicamente, 129.690 participantes con obesidad únicamente, y?130.216 participantes con T2DM y obesidad. La semaglutida no se asoció con un mayor riesgo de NAION entre personas con T2DM únicamente, obesidad únicamente y, tanto T2DM como obesidad, y los resultados fueron consistentes en períodos de seguimiento de 1, 2, o 3 a?os. #Ophthalmology #ophthotwitter #eyecare

Ophthopedia Update:Abstracts: Cameron Duic, BS, Emily Vance, MPH, Elvira Agrón, MA, Tiarnán D.L. Keenan, BM BCh, PhD, the AREDS2 Research Group #Ophthalmology #ophthotwitter #eyecare

Ophthopedia Update:Contents #Ophthalmology #ophthotwitter #eyecare

Ophthopedia Update:Editorial Board #Ophthalmology #ophthotwitter #eyecare